iBio, Inc. (IBIO) Dividend History

iBio, Inc. is a biotechnology company that specializes in the development and production of plant-based biopharmaceutical products. Using proprietary plant-based expression systems, the company focuses on creating vaccines, monoclonal antibodies, and other therapeutic proteins. iBio aims to leverage its technology to provide cost-effective and scalable solutions for the development of biologics and vaccines.

Dividend History

iBio, Inc. currently does not pay dividends

Company News

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio has in-licensed a potentially best-in-class long-acting anti-myostatin antibody from AstralBio and is launching a new program featuring a myostatin + activin A bispecific antibody designed to promote weight loss, prevent muscle loss and weight regain.

GlobeNewswire Inc.
Biopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments

The biopharmaceuticals contract manufacturing market is expected to grow at a steady CAGR due to the increasing prevalence of chronic diseases, growing R&D investments in biologics and biosimilars, and the rise in outsourcing by biopharma giants to streamline drug development.

GlobeNewswire Inc.

Featured Companies: ABBV ADMA BAX PFE
iBio to Participate in Upcoming Investor Conferences

iBio, Inc., an AI-driven innovator of precision antibody immunotherapies, announced that its CEO and CFO will participate in upcoming investor conferences, including the H.C. Wainwright 26th Annual Global Investment Conference and the 2024 Cantor Global Healthcare Conference.

GlobeNewswire Inc.
iBio Closes Sale of Manufacturing Facility in Texas

– The sale of the facility eliminates $13.2M of secured debt –

GlobeNewswire Inc.
iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 08:18:18 UTC